Allogene Therapeutics, Inc. share price logo

Allogene Therapeutics, Inc. Share Price

NASDAQ: ALLO

Small Cap

$2.08

-0.14

(-6.08%)

as on

Allogene Therapeutics, Inc. Stock Performance

as on March 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $2.06
    $2.26
    downward going graph

    0.96%

    Downside

    8.65%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.86
    $2.80
    downward going graph

    58.55%

    Downside

    34.62%

    Upside

    downward going graph

Allogene Therapeutics, Inc. share price movements today

Previous Close
$2.22
Open
$2.23
Volume
6.8M
Day's Low - High
$2.06 - $2.26
52 Week Low - High
$0.86 - $2.80

Allogene Therapeutics, Inc. Historical Returns

1 Month Return
+ 0.98 %
3 Month Return
+ 45.77 %
1 Year Return
+ 27.78 %
3 Year Return
-61.38 %
5 Year Return
-94.41 %

Allogene Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Allogene Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$498.9M

EPS (TTM)

-0.7055

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.97

Industry PE ratio

-4.746406779661017

PEG Ratio

0

EBITDA

-194.6M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-53.42%

Allogene Therapeutics, Inc. Stock Valuation

Track how Allogene Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Allogene Therapeutics, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-18.43x)

March 31, 2021

Industry (-4.75x)

March 21, 2026

Today (-1.97x)

March 21, 2026

Highest (-1.20x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.97x

Allogene Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Allogene Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Allogene Therapeutics, Inc. image
Allogene Therapeutics, Inc.
BUY$498.9M-94.41%-1.970.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.3B116.54%133.528.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$116.3B110.08%29.9432.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.5BNA114.935.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.0B54.71%17.831.41%

Stock Returns calculator for Allogene Therapeutics, Inc. Stock including INR - Dollar returns

The Allogene Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Allogene Therapeutics, Inc. investment value today

Current value as on today

₹1,37,840

Returns

₹37,840

(+37.84%)

Returns from Allogene Therapeutics, Inc. Stock

₹28,395 (+28.4%)

Dollar Returns*

₹9,445 (+9.44%)

Analyst Recommendation on Allogene Therapeutics, Inc. Stock

Based on 23 analysts

BUY

73.91%

Buy

26.09%

Hold

0.00%

Sell

Based on 23 analysts, 73.91% of analysts recommend a 'BUY' rating for Allogene Therapeutics, Inc.. Average target price of $7.47

Allogene Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Allogene Therapeutics, Inc..

What analysts predicted

72.16%UPSIDE

Target Price

$7.47

Current Price

$2.08

Analyzed by

23 Analysts

Target

$7.47

Allogene Therapeutics, Inc. target price $7.47, a slight upside of 72.16% compared to current price of $2.08. According to 23 analysts rating.

Allogene Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Allogene Therapeutics, Inc. Stock has increased by 59% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:59% versus previous 30 day period

Allogene Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
-
-
0
-
-
-
-
Gross Profit
-3
0
-3
-3
-3
-3
-3
-3
-31
-3
Operating Income
-62
-85
-69
-71
-71
-60
-65
-56
-44
-42
EBITDA
-58
-68
-61
-62
-62
-56
-56
-47
-37
-39
Interest Expense
-
0
-
-
0
0
0
0
0
0
Depreciation
3
3
3
3
3
3
3
3
3
3
Income Before Tax
-62
-89
-65
-66
-66
-59
-59
-50
-41
-38
Income Tax Expense
-6
0
3
0
-
0
-
-
-
-
Net Income
-62
-89
-65
-66
-66
-59
-59
-50
-41
-38
Net Profit Margin
-283122.73%
202856.82%
-295454.55%
0.00%
0.00%
272450.00%
0.00%
0.00%
0.00%
0.00%

Allogene Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
38
38
0
0
0
-
Gross Profit
-
-1
-5
-11
38
0
0
0
-12
Operating Income
0
-192
-202
-258
-255
-335
-327
-273
-206
EBITDA
0
-206
-179
-250
-245
-321
-313
-243
-194
Interest Expense
-
3
5
9
10
17
17
0
1
Depreciation
-
1
5
7
10
14
13
13
12
Income Before Tax
0
-211
-184
-250
-257
-332
-327
-257
-190
Income Tax Expense
0
0
0
-16
-12
-2
-2
0
-
Net Income
0
-211
-184
-233
-244
-329
-327
-257
-190
Net Profit Margin
0.00%
0.00%
0.00%
-608.87%
-636.12%
-135726.34%
-344489.47%
-1170863.64%
0.00%

Allogene Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-89
-65
-66
-66
-59
-59
-50
-41
-38
Operating Cash Flow
-53
-55
-63
-44
-36
-52
-39
-29
-27
Investing Cash Flow
67
22
74
-75
54
6
43
11
33
Financing Cash Flow
0
1
108
0
5
13
5
3
7
Change in Cash
13
-32
119
-119
23
-32
9
-14
13

Allogene Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-211
-184
-250
-257
-332
-327
-257
-190
Operating Cash Flow
-44
-137
-115
-184
-220
-237
-200
-149
Investing Cash Flow
-632
164
-505
163
106
163
75
95
Financing Cash Flow
771
58
633
11
2
95
116
30
Change in Cash
93
85
13
-9
-111
21
-7
-23

Global Institutional Holdings in Allogene Therapeutics, Inc.

Funds
Holdings
Pfizer Inc
9.8%
Geode Capital Management, LLC
1.75%
UBS Group AG
1.59%
AQR Capital Management LLC
0.82%
Woodline Partners LP
1.56%
See all

Insights on Allogene Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 7 quarters, -66.35M → -38.81M (in $), with an average increase of 9.7% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ALLO has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Allogene Therapeutics, Inc. has experienced a drawdown of -58.9%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 56.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 22.0K → -22.0K (in $), with an average decrease of 200.0% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ALLO stock has moved down by -13.8%

About Allogene Therapeutics, Inc.

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
OrganisationAllogene Therapeutics, Inc.
Headquarters210 East Grand Avenue, South San Francisco, CA, United States, 94080
IndustryHealth Technology
CEODr. David D. Chang M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Allogene Therapeutics, Inc.

Name

Title

Dr. Zachary J. Roberts M.D., Ph.D.

Executive VP of Research & Development and Chief Medical Officer

Ms. Susan R. Lundeen

Chief People Officer

Ms. Christine Cassiano

Executive VP, Chief Corporate Affairs & Brand Strategy Officer

Ms. Annie Yoshiyama

SVP & Corporate Controller

Mr. Earl M. Douglas Esq.

Senior VP, General Counsel, Compliance Officer & Corporate Secretary

Dr. Arie S. Belldegrun F.A.C.S., M.D.

Co-Founder & Executive Chairman

Dr. David D. Chang M.D., Ph.D.

Co-Founder, President, CEO & Director

Mr. Joshua A. Kazam

Co-Founder & Director

Mr. Geoffrey M. Parker

Executive VP & CFO

Mr. Benjamin M. Beneski

Senior VP & Chief Technical Officer

FAQs

What is Allogene Therapeutics, Inc. share price today?

Allogene Therapeutics, Inc. share price today is $2.08 as on at the close of the market. Allogene Therapeutics, Inc. share today touched a day high of $2.26 and a low of $2.06.

What is the 52 week high and 52 week low for Allogene Therapeutics, Inc. share?

Allogene Therapeutics, Inc. share touched a 52 week high of $2.8 on and a 52 week low of $0.86 on . Allogene Therapeutics, Inc. stock price today i.e. is closed at $2.08,which is 25.71% down from its 52 week high and 141.27% up from its 52 week low.

What is Allogene Therapeutics, Inc.'s market capitalisation today?

Allogene Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Allogene Therapeutics, Inc. Stock (ALLO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Allogene Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Allogene Therapeutics, Inc. Shares that will get you 0.7212 shares as per Allogene Therapeutics, Inc. share price of $2.08 per share as on March 21, 2026 at 1:29 am IST.

What is the minimum amount required to buy Allogene Therapeutics, Inc. Stock (ALLO) from India?

Indian investors can start investing in Allogene Therapeutics, Inc. (ALLO) shares with as little as ₹93.652 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹936.52 in Allogene Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Allogene Therapeutics, Inc. share’s latest price of $2.08 as on March 21, 2026 at 1:29 am IST, you will get 4.8077 shares of Allogene Therapeutics, Inc.. Learn more about fractional shares .

What are the returns that Allogene Therapeutics, Inc. has given to Indian investors in the last 5 years?

Allogene Therapeutics, Inc. stock has given -94.41% share price returns and 28.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?